These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 26687593)

  • 1. Venetoclax targets BCL2 in chronic lymphocytic leukaemia.
    Brower V
    Lancet Oncol; 2016 Jan; 17(1):e11. PubMed ID: 26687593
    [No Abstract]   [Full Text] [Related]  

  • 2. New Agents to Treat Chronic Lymphocytic Leukemia.
    Roberts AW; Davids MS; Seymour JF
    N Engl J Med; 2016 Jun; 374(22):2186-7. PubMed ID: 27248631
    [No Abstract]   [Full Text] [Related]  

  • 3. New Agents to Treat Chronic Lymphocytic Leukemia.
    Zaman F; Savendahl L
    N Engl J Med; 2016 Jun; 374(22):2185. PubMed ID: 27248632
    [No Abstract]   [Full Text] [Related]  

  • 4. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
    [No Abstract]   [Full Text] [Related]  

  • 5. Progress in Chronic Lymphocytic Leukemia with Targeted Therapy.
    Wilson WH
    N Engl J Med; 2016 Jan; 374(4):386-8. PubMed ID: 26816016
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
    Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
    N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax in the treatment of chronic lymphocytic leukemia.
    Korycka-Wolowiec A; Wolowiec D; Kubiak-Mlonka A; Robak T
    Expert Opin Drug Metab Toxicol; 2019 May; 15(5):353-366. PubMed ID: 30969139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A literature review of the patent publications on venetoclax - a selective Bcl-2 inhibitor: discovering the therapeutic potential of a novel chemotherapeutic agent.
    Žigart N; Časar Z
    Expert Opin Ther Pat; 2019 Jul; 29(7):487-496. PubMed ID: 31154862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
    King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
    Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia.
    Seymour J
    Clin Adv Hematol Oncol; 2019 Aug; 17(8):440-443. PubMed ID: 31449511
    [No Abstract]   [Full Text] [Related]  

  • 12. Practical Dosing Considerations for Venetoclax.
    Valla K
    Oncology (Williston Park); 2019 Sep; 33(9):. PubMed ID: 31571184
    [No Abstract]   [Full Text] [Related]  

  • 13. Venetoclax plus rituximab for chronic lymphocytic leukaemia.
    Stirrups R
    Lancet Oncol; 2018 May; 19(5):e233. PubMed ID: 29606585
    [No Abstract]   [Full Text] [Related]  

  • 14. Venetoclax Adds a New Arrow Targeting Relapsed CLL to the Quiver.
    Rogers KA; Byrd JC
    Cancer Cell; 2016 Jan; 29(1):3-4. PubMed ID: 26766586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABT-199 for chronic lymphocytic leukemia.
    Seymour J
    Clin Adv Hematol Oncol; 2014 Oct; 12(10):698-700. PubMed ID: 25658896
    [No Abstract]   [Full Text] [Related]  

  • 16. A BH3 Mimetic for Killing Cancer Cells.
    Green DR
    Cell; 2016 Jun; 165(7):1560. PubMed ID: 27315468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment.
    Salem AH; Dave N; Marbury T; Hu B; Miles D; Agarwal SK; Bueno OF; Menon RM
    Clin Pharmacokinet; 2019 Aug; 58(8):1091-1100. PubMed ID: 30949874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax.
    Innocenti I; Morelli F; Autore F; Tomasso A; Corbingi A; Bellesi S; Za T; De Stefano V; Laurenti L
    Leuk Lymphoma; 2019 Dec; 60(12):3078-3080. PubMed ID: 31106622
    [No Abstract]   [Full Text] [Related]  

  • 19. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
    Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
    Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
    Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
    Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.